EyePoint Inc

EYPT

Market cap $1.16B

Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives

Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities' top picks for the month.

Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint said on Thursday an independent safety committee found no new concerns in ​two late-stage trials of its experimental eye disease drug ‌Duravyu and recommended the studies continue unchanged.

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after –  – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical trials –  – All active patients in the treatment arm have reached their second DURAVYU dosing visit, with over 35% receiving a third dose – WATERTOWN, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled review of the Company's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD) and recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications.